Launches business unit to create AI psychiatrist focused on reducing inflammation Vyome remains fully funded through 2026 to unlock value from core assets CAMBRIDGE, Mass. / Sep 29, 2025 / Business Wire / Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced it has acquired substantially all of the assets of Oculo, Inc., an AI startup launched at the Massachusetts Institute of... Read More

Vyome’s offering is a first-of-its-kind in a broader $20B potential addressable ocular inflammation market VT-1908 eyedrop achieves the desired concentration in the anterior chamber of the eye and significantly reduces uveitis score in preclinical models (P<0.001) CAMBRIDGE, Mass. / Sep 17, 2025 / Business Wire / Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, presented results from its... Read More

Dr. Richard Fahrner and Dr. Tamara Agajanov add expertise in accelerated approvals CAMBRIDGE, Mass. / Sep 09, 2025 / Business Wire / Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard Fahrner as Chief Technology Officer and Dr. Tamara Agajanov, MD, as Senior Vice President – Clinical Development. Dr. Fahrner brings to Vyome over 25 years of... Read More

VT-1953 continues to significantly improve the primary endpoint Co-founder Dr. Shiladitya Sengupta to discuss over a live video conference VT-1953 treatment significantly reduced malignant fungating wound-associated malodor (primary endpoint) (P<0.001). Patients also reported significant improvements in lesion pain (P<0.001) and Quality of Life (P<0.001), both secondary and exploratory endpoints, respectively. CAMBRIDGE,... Read More

Vyome seeks to access multi-billion-dollar AI-enabled medical device market CAMBRIDGE, Mass. & PUNE, India / Aug 21, 2025 / Business Wire / Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, and Embryyo Technologies today announced the signing of an MoU (Memorandum of Understanding) to jointly pursue the global AI-enabled medical device market. This partnership will combine Vyome's healthcare... Read More

Celebrates Indian Independence Day by Honoring the US-India Innovation Partnership CAMBRIDGE, Mass. / Aug 15, 2025 / Business Wire / Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare holding company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, will be ringing the Nasdaq Opening Bell today in honor of its first day of trading as “HIND.” The occasion will... Read More

CAMBRIDGE, Mass. / Aug 14, 2025 / Business Wire / Vyome Therapeutics, Inc. (“Vyome”), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that it has closed the previously disclosed transaction with ReShape Lifesciences Inc. (Nasdaq: RSLS). The post-merger company will trade at the open of trading on Friday, August 15,... Read More

Effective as of Commencement of Trading on August 15, 2025 CAMBRIDGE, Mass. / Aug 13, 2025 / Business Wire / Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that The Nasdaq Stock Market has approved its listing upon completion of the Company’s previously announced merger with ReShape... Read More

Heavily shareholder-aligned board and management team completely replaces ReShape team as Vyome prepares for public listing on August 15, 2025 CAMBRIDGE, Mass. / Aug 12, 2025 / Business Wire / Vyome Therapeutics, Inc. , a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced its post-closing Board of Directors, expected to... Read More

Expected to be Effective as of Commencement of Trading on August 15, 2025 IRVINE, Calif. / Aug 07, 2025 / Business Wire / ReShape Lifesciences ® (Nasdaq: RSLS) announced today that its shareholders have approved all of the proposals necessary to complete the previously announced merger with Vyome Therapeutics, which is expected to be effective for the commencement of trading on Friday, August 15, 2025. The shares of common... Read More

Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved Stockholders are encouraged to vote FOR Proposals 2 and 3 by Calling 1-877-750-8310 (from the U.S. and Canada) or +1-412-232-3651 (from other countries) IRVINE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led... Read More

Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025 IRVINE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will host its inaugural Lap-Band ® Surgeon Summit, taking place August 1-3, 2025 in Nashville, Tennessee. Dr. Christine Ren-Fielding, M.D.,... Read More

Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys Shareholders are encouraged to vote FOR Proposals 1, 2, and 3 by Calling 1-877-750-8310 IRVINE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will host a... Read More

Patent Enhances and Broadens the Company’s Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device IRVINE, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on July 8, 2025 the U.S. Patent and Trademark Office (USPTO) will issue U.S. Patent 12,350,179, entitled,... Read More

IRVINE, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on June 23, 2025, it received formal notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq's stockholders equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) and... Read More

Reduction in Force Estimated to Save Over $750K or 23.4% of Annual Payroll Expenses Agreements Progress Toward Completion; Shareholder Meeting Scheduled for July 24, 2025 IRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced strategic headcount reduction and provided an update on the merger... Read More

Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was granted a key international patent from the Australian Patent Office for its Diabetes Neuromodulation technology. Patent number... Read More

Recon Supply Named Exclusive U.S. Distributor of ReShape’s STIMEL-03, Lap-Band® 2.0 FLEX, and Full Product Portfolio to Reach U.S. Veterans and Active-Duty Service Members IRVINE, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of an exclusive U.S. distribution agreement with Recon... Read More

IRVINE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (“ReShape” or the “Company”) (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its public offering of 1,054,604 shares of common stock at a public offering price of $2.50 per share. Gross proceeds from the offering are expected to be approximately $2.6 million before deducting... Read More

IRVINE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Quality Management System (QMS) and entire commercial portfolio of medical devices sold in Europe and in the United Kingdom (UK) have been certified under the European Union (EU) Medical Device Regulation (MDR) (EU) 2017/745 and UK... Read More

Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Progress Towards Completion IRVINE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2025 and provided a corporate strategic update. First Quarter 2025 and... Read More

IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-25 reverse stock split of the company’s common stock, which will be effective for trading purposes upon the commencement of trading on May 9, 2025. At that time, each 25 shares of issued and... Read More

Vagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia Device Demonstrates the Ability to Modulate Glucose Levels Without Cardiac Side Effects, Overcoming a Key Limitation Of Conventional Vagal Stimulation Techniques IRVINE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced... Read More

IRVINE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/241,151, entitled, “Intragastric Device.” When issued, the patent will cover claims for an intragastric balloon... Read More

Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia Patent Enables Equivalent Efficacy with 10 times Lower Energy Consumption Than Current Device Fully Compatible with Standard Implantable Pulse Generators, Enabling Cost-Effective Development IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic... Read More

IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has signed an agreement with Haifa, Israel-based Motion Informatics to exclusively import and distribute their next-generation neuromuscular rehabilitation devices in the U.S. The flagship product, the Stimel-03, was showcased at the... Read More

Significant Reduction in Overall Operating Expenses of 41.9% in 2024, Excluding M&A Related Expenses, Compared to 2023 Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Remain on Track Strategic Business Update Call to be Held Thursday, April 10, at 4:30 pm ET IRVINE, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight... Read More

IRVINE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 17/046,677, entitled, “Simultaneous Multi-Site Vagus Nerve Modulation for Improved Glycemic Control System and... Read More

IRVINE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has signed a distribution agreement with Liaison Medical for distribution of ReShape’s next generation, enhanced Lap-Band ® 2.0 FLEX and Tubing Kit, in Canada. “The signing of this distribution agreement in Canada, on the heels of the... Read More

IRVINE, Calif., Feb. 15, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (“ReShape” or the “Company”) (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its public offering of 2,575,107 units at a public offering price of $2.33 per unit. Each unit consists of one common share (or pre-funded warrant to purchase one common share in-lieu thereof) and one... Read More

IRVINE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was granted a key international patent from the State of Israel Patent Office for its Diabetes Neuromodulation technology. Patent Number 277949, entitled, “Simultaneous Multi-Site Vagus Nerve Modulation for Improved Glycemic... Read More

IRVINE, Calif. and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, and Vyome Therapeutics, Inc. (“Vyome”), a private clinical-stage company targeting immuno-inflammatory and rare diseases, today provided an update on the definitive merger agreement under which ReShape and Vyome will combine in an... Read More

CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vyome Therapeutics , a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, announced today that it has signed a merger agreement with ReShape Lifesciences (Nasdaq: RSLS). Upon closing, it is anticipated that the post-merger entity, will be renamed Vyome Holdings, Inc., and continue to... Read More

ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory Diseases of Unmet Need, to Combine in All-Stock Merger ReShape to Sell its Assets to Affiliate of Biorad Medisys for $5.16 Million IRVINE, Calif. and CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, and... Read More

Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 Implementation of 2024 Cost Reduction Plan Continues, Expected to Reduce Operating Expenses by 55.4% Compared to 2023 Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences... Read More

IRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the first quarter ended March 31, 2024, including a corporate update on Wednesday, May 15, 2024, after market. Management will host a conference call on May 15 at 4:30 pm ET. A live webcast will be... Read More

Completed First Surgeries With Next-Generation Lap-Band ® 2.0 FLEX 2024 Operating Expenses Expected to Decrease by more than 50% Compared to 2023; Reaffirming Commitment to Profitability Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported... Read More

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/370,819, entitled, “Intragastric Device.” When issued, the patent will cover claims for an intragastric balloon... Read More

2024 Operating Expenses Expected to Decrease by 55.4% Compared to 2023 Company Reaffirms Commitment to Profitability High Priority Search for Synergistic M&A Partner Continues IRVINE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced a 2024 cost reduction plan and reorganization to prioritize the... Read More

FLEX Technology Designed to Enhance the Patient Experience Surgeon Training Underway for the Initial Launch of the Lap-Band ® 2.0 FLEX IRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Adam Smith, D.O., Bariatric Surgery Specialist and Chief Executive Officer of Ultimate Bariatrics in... Read More

IRVINE, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that bariatric surgical fellows from the University of Texas Health Center in Houston, Texas were trained on Friday, January 19 th , on the Lap-Band® System and also received an introduction to the Company’s new Lap-Band® 2.0 FLEX. The training... Read More

IRVINE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it has engaged Maxim Group LLC, to act as the Company’s exclusive financial advisor to identify potential strategic merger and acquisition partnership alternatives. The Company does not have a defined timeline for such a transaction and... Read More

FLEX Technology Designed to Improve the Patient Experience Company Initiating U.S. Product Launch IRVINE, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of a PMA supplement for the company’s next generation, enhanced Lap-Band ®... Read More

IRVINE, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences, Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, announced today that it has entered into a warrant exercise agreement with an existing accredited investor to exercise outstanding warrants to purchase an aggregate of 5,382,500 shares of the company’s common stock. In consideration for the immediate... Read More

Third Quarter Core Operating Expenses Reduced 37% Compared to Third Quarter of 2022 Cost Reduction Plan To Reduce Operating Expenses In 2024 by Over 40% Compared to 2023 Conference Call to be Held at 5:00 pm ET Today IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the... Read More

IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the third quarter ended September 30, 2023, including a corporate update on Wednesday, November 8, 2023, after market. Management will host a conference call on November 8 at 5:00 pm ET. A live... Read More

IRVINE, Calif., Sept. 29, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its public offering of 9,100,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock in lieu thereof), and warrants to purchase one and one half shares of... Read More

IRVINE, Calif., Sept. 22, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer, and Tom Stankovich, Chief Financial Officer, will present a company overview on Tuesday, October 3, 2023 at 3:30 PM PT, at LD Micro’s 16th Annual Main Event, taking place October... Read More

IRVINE, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of an exclusive, royalty-bearing license agreement with Biorad Medysis, Pvt. Ltd. (Biorad) to manufacture, commercialize and distribute the Obalon® Gastric Balloon System in India, Pakistan, Bangladesh, Nepal, Bhutan, Sri Lanka,... Read More

IRVINE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS) , the premier physician-led weight loss and metabolic health solutions company, today announced that the company has significantly strengthened the patent portfolio related to its Obalon ® Balloon System. Specifically, the U.S. Patent and Trademark Office (USPTO) has granted one patent and provided the company with a Notice of Allowance... Read More

IRVINE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was awarded a $331,541 Small Business Innovation Research (SBIR) grant for the development of ReShape’s Diabetes Bloc-Stim Neuromodulation ™ (DBSN ™ ) device, which utilizes its proprietary vagus nerve block (vBloc) technology... Read More

Company Executing Its Plan for Growth; Achieves Continued Improvement in Operational Effectiveness Reducing Second Quarter Operating Expenses by 53% Compared to Second Quarter of 2022 Conference Call to be Held at 5:00 pm ET Today SAN CLEMENTE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported... Read More

IRVINE, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the second quarter ended June 30, 2023, including a corporate update on Monday, August 7, 2023, after market. Management will host a conference call at 5:00 pm ET the same day and will be joined... Read More

IRVINE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of a preferred partner agreement with Hive Medical (Hive). Hive’s software suite leverages AI, machine-learning, SMS, and patient self-service technology to increase patient volume. “Our agreement with Hive is expected to... Read More

IRVINE, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today presented data on its proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device in an e-poster at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2023 Annual Meeting, being held in Las Vegas, NV, June 25 - 29, 2023. “Type 2... Read More

IRVINE, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the submission of a Premarket Approval (PMA) supplement application to the U.S. Food and Drug Administration (FDA) for the company’s next generation, enhanced Lap-Band ® 2.0, utilizing a band reservoir technology. “The PMA supplement submission... Read More

SAN CLEMENTE, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS) , the premier physician-led weight loss and metabolic health solutions company, today announced participation in the following investor and industry conferences in June: June 20-21: Maxim Virtual Healthcare Conference. Paul F. Hickey, President and Chief Executive Officer, and Tom Stankovich, Chief Financial Officer, will present... Read More

Achieved Continued Improvement in Operational Effectiveness With First Quarter 2023 Operating Expenses Down 42.9% Compared to the First Quarter of 2022 Executing a Plan For Growth and Profitability With a Balance Sheet Bolstered By Approximately $12.7 Million Raised in 2023 Conference Call to be Held at 4:30 pm ET Today SAN CLEMENTE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the... Read More

SAN CLEMENTE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the first quarter ended March 31, 2023, including a corporate update on Monday, May 15, 2023, after market. Management will host a conference call on May 15 at 4:30 pm ET. A live webcast will... Read More

SAN CLEMENTE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences ™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will present data on its proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device in a poster at the Keystone Symposia on Type 2 Diabetes: Understanding its Early Drivers and the Road to Therapeutics, being held in Palm Springs,... Read More

Continued Sequential Quarterly Growth in the U.S. With Q4 Revenues of $2.7 Million Improved Operational Effectiveness With Second Half 2022 Operating Expenses Down 27.9% Compared to the First Half of 2022, A $5.1 Million Reduction Executing A Plan For Profitability With A Balance Sheet Bolstered By Approximately $16.0 Million Raised Over the Last 12 Months Conference Call to be Held at 4:30 pm ET Today SAN CLEMENTE, Calif.,... Read More

SAN CLEMENTE, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 800,695 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market... Read More

SAN CLEMENTE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences ™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/792,094, entitled, “Systems and Methods for Determining Failure of Intragastric Devices,” related to its... Read More

SAN CLEMENTE, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will delay its year ended December 31, 2022 earnings release and conference call, previously scheduled for 8:00 am ET on March 29, 2022. The delay is required to allow the company additional time to complete its year end... Read More

SAN CLEMENTE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced the formation of a Scientific Advisory Board (SAB). Members include internationally recognized experts and surgeons in the obesity and metabolic disease fields. The newly created SAB will provide management with strategic input and... Read More

SAN CLEMENTE, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the year ended December 31, 2022, including a corporate update, on Wednesday, March 29, 2023, pre-market. Management will host a conference call on March 29 at 8:00 am ET. A live webcast... Read More

SAN CLEMENTE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer, and Tom Stankovich, Chief Financial Officer, will present a company overview at the Q2 Virtual Investor Summit on Wednesday, March 29 at 1:00 pm ET. During the virtual... Read More

SAN CLEMENTE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the closing of its upsized underwritten public offering of 1,275,000 units, with each unit consisting of one share of its common stock, or one pre-funded warrant to purchase one share of its common stock, and one warrant to purchase one... Read More

SAN CLEMENTE, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its upsized underwritten public offering of 1,275,000 units, with each unit consisting of one share of its common stock, or one pre-funded warrant to purchase one share of its common stock, and one warrant to purchase one... Read More

SAN CLEMENTE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-50 reverse stock split of the company’s common stock, which will be effective for trading purposes upon the commencement of trading on December 23, 2022. At that time, each 50 shares of... Read More